ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "osteo-anabolics"

  • Abstract Number: 321 • 2016 ACR/ARHP Annual Meeting

    Results of a Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Romosozumab in Men with Osteoporosis

    EM Lewiecki1, S Horlait2, T Blicharski3, S Goemaere4, K Lippuner5, P Meisner6, PD Miller7, A Miyauchi8, J Maddox9, NS Daizadeh9 and A Grauer9, 1New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, 2Amgen Ltd., Uxbridge, United Kingdom, 3Medical University of Lublin, Lublin, Poland, 4Ghent University Hospital, Gent, Belgium, 5Bern University Hospital, Bern, Switzerland, 6UCB Pharma, Brussels, Belgium, 7Colorado Center for Bone Research, Lakewood, CO, 8Miyauchi Medical Center, Osaka, Japan, 9Amgen Inc., Thousand Oaks, CA

    Background/Purpose: Treatment with romosozumab (Romo) has been shown to rapidly increase BMD in postmenopausal women with low BMD through a dual effect on bone, increasing…
  • Abstract Number: 1023 • 2016 ACR/ARHP Annual Meeting

    Fracture Risk Reduction with Romosozumab: Results of a Phase 3 Study in Postmenopausal Women with Osteoporosis

    F Cosman1, DB Crittenden2, JD Adachi3, N Binkley4, E Czerwinski5, S Ferrari6, LC Hofbauer7, E Lau8, EM Lewiecki9, A Miyauchi10, CAF Zerbini11, CE Milmont2, L Chen2, J Maddox2, PD Meisner12, C Libanati12 and A Grauer2, 1Helen Hayes Hospital, West Haverstraw, and Columbia University, New York, NY, 2Amgen Inc., Thousand Oaks, CA, 3McMaster University, Hamilton, ON, Canada, 4University of Wisconsin–Madison Osteoporosis Clinical Center and Research Program, Madison, WI, 5Krakow Medical Center, Krakow, Poland, 6Geneva University Hospital, Geneva, Switzerland, 7Division of Endocrinology, Diabetes, and Bone Diseases, TU Dresden Medical Center, Dresden, Germany, 8Center for Clinical and Basic Research, Hong Kong, China, 9New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, 10Miyauchi Medical Center, Osaka, Japan, 11Centro Paulista de Investigação Clinica, São Paulo, Brazil, 12UCB Pharma, Brussels, Belgium

    Background/Purpose:  Romosozumab (Romo) is an investigational bone-forming monoclonal antibody that binds sclerostin and has a dual effect, increasing bone formation and decreasing bone resorption. Here,…
  • Abstract Number: 1024 • 2016 ACR/ARHP Annual Meeting

    Superior Gains in Bone Mineral Density and Estimated Strength at the Hip for Romosozumab Compared with Teriparatide in Women with Postmenopausal Osteoporosis Transitioning from Bisphosphonate Therapy: Results of a Phase 3, Open-Label Clinical Trial

    B Langdahl1, C Libanati2, DB Crittenden3, MA Bolognese4, JP Brown5, NS Daizadeh3, K Engelke6, HK Genant7, S Goemaere8, Lars Hyldstrup9, E Jodar-Gimeno10, TM Keaveny11, D Kendler12, P Lakatos13, J Maddox3, J Malouf14, FE Massari15, JF Molina16, MR Ulla17 and A Grauer3, 1Aarhus University Hospital, Aarhus, Denmark, 2UCB Pharma, Brussels, Belgium, 3Amgen Inc., Thousand Oaks, CA, 4Bethesda Health Research Center, Bethesda, MD, 5Laval University and CHU de Québec (CHUL) Research Centre, Quebec City, QC, Canada, 6BioClinica Inc., Hamburg, Germany, 7Department of Radiology, University of California San Francisco, San Francisco, CA, 8Ghent University Hospital, Gent, Belgium, 9Hvidovre University Hospital, Hvidovre, Denmark, 10Servicio de Endocrinología, Hospital Universitario Quirón, Madrid, Spain, 11University of California at Berkeley, Berkeley, CA, 12University of British Columbia, Vancouver, BC, Canada, 13Department of Medicine, Semmelweis University, Budapest, Hungary, 14Universitat Autònoma de Barcelona, Barcelona, Spain, 15Instituto de Investigaciones Metabólicas, Buenos Aires, Argentina, 16Reumalab Centro Integral de Reumatologia, Medellin, Colombia, 17Instituto Latinoamericano de Investigaciones Médicas, Córdoba, Argentina

    Background/Purpose:  STRUCTURE was a phase 3, open-label study evaluating the effect of romosozumab or teriparatide for 12 months in women with postmenopausal osteoporosis transitioning from…
  • Abstract Number: 2499 • 2016 ACR/ARHP Annual Meeting

    Tocilizumab Achieves Rapid Reduction of Disease Activity and Has Beneficial Effects on Bone Mineral Density in Patients with Rheumatoid Arthritis

    Maria Hoehle, Rheumatology, Hamburg, Germany

    Tocilizumab achieves rapid reduction of disease activity and has beneficial effects on bone mineral density in patients with rheumatoid arthritis Maria Höhle, MD11Orthopedic, Medical, Rheumatologic…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
This site uses cookies: Find out more.